Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)
The primary aims of this study are to assess:
- The inter-rater and test-retest reliability of the MINI-KID
- The validity of the standard MINI-KID interview in relation to the parent rated pencil/paper version (MINI-KID-P) and th longer clinician rated "Schedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version (K-SADS-PL) and "expert opinion" (when available).
Secondary aims will include evaluating the concordance between: The Children's Global Assessment Scale (a required part of the K-SADS) with the clinician-rated Sheehan Disability Scale (to be administered with the MINI-KID) as a measure of illness severity.
Oppositional Defiant Disorder
Pervasive Developmental Disorder
|Study Design:||Observational Model: Case-Only
Time Perspective: Cross-Sectional
|Official Title:||Reliability and Validity of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)|
- Kappa scores between MINI Kid and K-SADS [ Time Frame: 4 years ]
|Study Start Date:||February 2004|
|Study Completion Date:||January 2008|
|Primary Completion Date:||January 2008 (Final data collection date for primary outcome measure)|
The MINI-KID is a short, structured diagnostic interview used to assess the presence of 24 DSM-IV child and adolescent psychiatric disorders as well as the risk of suicide.
To achieve adequate representation of the major psychiatric disorders and sufficient normal controls, we propose recruiting 230 children and adolescents (ages 6 to 17 years 11 months), comprised of 200 subjects identified as having one or more psychiatric disorders and 30 normal controls in the community. These subjects will be from diverse socioeconomic, racial and ethnic backgrounds. We will assess the inter-rater and test-retest reliability of the MINI-KID and examine its validity with the "gold-standard" diagnostic interview for children and adolescents as well as expert opinion.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00579267
|United States, Florida|
|University of South Florida College of Medicine, Department of Psychiatry|
|Tampa, Florida, United States, 33613-4788|
|Principal Investigator:||David V. Sheehan, MD, MBA||University of South Florida College of Medicine|